Scaling Femtech in Europe
Join a curated conversation bringing together leading voices across the Femtech ecosystem from breakthrough biotech founders to institutional leaders, focused on what it truly takes to scale.
With women's health historically underfunded relative to its market potential, the sector is drawing increasing attention from investors looking at diagnostics, therapeutics, digital health, and medtech solutions designed specifically for female biology. This gathering brings together founders and investors to explore what scaling femtech actually looks like in the European market, from regulatory pathways to funding dynamics and the commercial strategies that are moving the needle.
Whether you are actively deploying capital in the space or building out your thesis around women's health, this is a focused conversation worth being part of.
What we’ll cover:
• The European landscape: A comparative look at France and Spain: regulatory dynamics, ecosystem maturity, and where opportunities are emerging.
• Market access & funding: Unlocking growth in a category still defining its pathways to scale and reimbursement.
• Institutional advocacy: How national organizations are accelerating the transition from innovation to standard of care.
Featuring innovators across the value chain:
Womed —> developing next-generation intrauterine therapies
Peekcell —> the innovation enables women’s cancer screening in the simplest possible way.
Aspivix —> soft-suction cervical device designed as a modern and gentler alternative to the tenaculum.
Femtech Spain —> represented by a board member shaping the national ecosystem
This event is organized by Capital Cell and VCLS. After this roundtable, you can interact with the panelists, startups, and the Capital Cell team during the networking cocktail hour to close out the night.